0VGI Stock Chart & Stats
$56.70
$0.00(0.00%)
At close: 4:00 PM EDT
$56.70
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$28.07 - $56.70
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
$7.96B
Enterprise Value$5.56K
Total Cash (Recent Filing)$514.43M
Total Debt (Recent Filing)$753.56M
Price to Earnings (P/E)16.4
Beta0.29
Next Earnings
Aug 03, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.18
Shares Outstanding153,083,570
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$63.86Price Target Upside12.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.32
Revenue Forecast (FY)$942.33M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum And GuidanceSustained patient uptake and consecutive quarterly growth underpin a durable revenue base. Management's raised guidance and an expected near‑$1B annualized run‑rate signal stronger channel adoption, broader physician acceptance, and scalable commercial execution that can support multi‑period revenue visibility and reinvestment.
High Gross And Net MarginsExceptional gross and net margins indicate powerful unit economics and pricing power in the BRIUMVI franchise. Margin sustainability supports cash generation potential (if converted) and allows reinvestment into lifecycle programs, R&D, and commercial expansion even as revenue growth normalizes.
Stronger Balance Sheet And Cash BufferA large cash balance and very low debt materially reduce refinancing and liquidity risk while enabling aggressive share repurchases and funding of subcutaneous scale‑up. This balance sheet strength supports near‑term R&D and manufacturing investments without forcing dilutive financing.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow despite strong reported net income weakens earnings quality and implies working‑capital or noncash drivers. Until cash conversion improves, the company faces execution risk funding operations and may need to rely on cash reserves for growth investments.
Material Gross-to-net/rebate PressureA sustained ~65% gross‑to‑net burden materially reduces realized revenue and limits margin expansion even if list sales grow. This structural payer and rebate dynamic can compress long‑term cash flows and necessitates continued payer strategy, potentially slowing net revenue per patient.
Shareholder Governance ConcernA failed say‑on‑pay vote signals investor dissatisfaction with compensation alignment and can trigger board scrutiny, potential management turnover, or policy changes. Governance tension may distract management, complicate incentive structures, and affect retention during a critical commercial and clinical expansion phase.
TG Therapeutics News
0VGI FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest share price was $28.07 and its highest was $56.70 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $7.96B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Aug 03, 2026 which is tomorrow.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on May 06, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.275 by -$0.155.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.31.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 153,083,570 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.12 in its last earnings report, missing expectations of $0.275. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in GB:0VGI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$63.86 (12.62% Upside)
$63.86 (12.62% Upside)
Blogger Sentiment
Bullish
GB:0VGI Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
132.81%
Trailing 12-Months
Company Description
TG Therapeutics
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
0VGI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum: record Q1 revenue, 63% YoY U.S. growth, rising patient counts (25,000+), improved profitability, a robust cash position and aggressive share buybacks. Management also highlighted multiple near‑term clinical catalysts (ENHANCE, subcutaneous readouts) and longer‑term expansion opportunities (subcutaneous formulation, additional indications). Offsetting this optimism are near‑term expense increases (including ~$100M subcutaneous spend), a one‑time refinancing charge, notable gross‑to‑net/rebate pressure (~65% guidance), and clinical/regulatory timing and outcome risks for key lifecycle programs and the azer‑cel program. Overall, the positives (strong revenue beats, guidance raises, cash and buybacks, lifecycle catalysts, and supportive long‑term data) materially outweigh the listed challenges, though execution and trial outcomes remain critical to sustaining the trajectory.View all GB:0VGI earnings summaries0VGI Stock 12 Month Forecast
Average Price Target
$63.86
▲(12.62% Upside)
Technical Analysis
Protagonist Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Legend Biotech
―
Kymera Therapeutics
―